Contents
Pernazinum is a drug used in psychiatry to treat acute and chronic schizophrenia as well as acute and chronic psychoses with delusions and hallucinations.
What is the composition and action of Pernazinum?
The active substance in Pernazinum is perazine dimaleate acting on the central nervous system. This substance has sedative and antipsychotic properties, as well as moderate antioxidant and anti-production (anti-inflammatory) properties. It has little effect on the extrapyramidal and vegetative systems. It also has antihistamine and antiemetic effects.
When is Pernazinum used?
The indications for taking Pernazinum are acute and chronic schizophrenia as well as acute and chronic psychosis. The drug is given to relieve the symptoms of delusions, anxiety, hallucinations and manic states. Pernazinum is also used in patients who are physically and mentally agitated.
Dosage of the drug Pernazinum
The drug Pernazinum is taken orally. The amount and frequency of use of the drug is determined by the doctor individually for a given patient. Alcohol must not be consumed during therapy with Pernazinum. Usually 50-150 mg of Pernazinum per day is administered, the maintenance dose for hospitalized patients is 200-600 mg of Pernazinum per day, administered in several doses. Pernazinum is intended for adults. There are no data on the effects of using it in children and adolescents.
Contraindications to the use of the drug Pernazinum
Pernazinum is not recommended for use in children and adolescents under 16 years of age. Contraindication to the use of Pernazinum are liver or kidney disorders, depression, epilepsy, Parkinson’s disease, too low blood pressure (hypotension), glaucoma and prostatic hyperplasia. Pernazinum should not be taken simultaneously with other drugs that depress the central nervous system, hypnotics, drugs that lower blood pressure, levodopa preparations and drugs for diabetes (insulin). Pernazinum is not recommended for patients with severe damage to the bone marrow or blood cells. It must not be used in coma and in patients with prolactin-dependent neoplasms (tumors). Pernazinum should not be used in pregnant and breastfeeding women, unless it is necessary and it exceeds the risk to the child’s health. Taking Pernazinum in the first trimester of pregnancy is particularly risky. Pernazinum is not recommended for patients with advanced ischemic heart disease and after a recent heart attack. Caution should be exercised in patients with organic brain injury and cerebrovascular disease. Pernazinum is also not recommended for the elderly.
Possible side effects of Pernazinum
The use of Pernazinum may cause symptoms of apathy and depression, weight gain, drop in blood pressure, disorders of the digestive and hematopoietic systems, and changes in blood counts.
Precautions when using the drug Pernazinum
Pernazinum may have a negative influence on the ability to drive vehicles. During treatment with Pernazinum, exposure to sunlight should be avoided (the drug increases the sensitivity of the skin to UV rays and may cause photosensitization). Pernazinum enhances the effect of other simultaneously taken antipsychotic drugs. Particular caution should be exercised with the simultaneous use of oral contraceptives.